X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs CIPLA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD CIPLA WYETH LTD/
CIPLA
 
P/E (TTM) x 27.7 33.8 82.0% View Chart
P/BV x 5.3 2.9 181.5% View Chart
Dividend Yield % 1.3 0.6 221.4%  

Financials

 WYETH LTD   CIPLA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
CIPLA
Mar-18
WYETH LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,044663 157.5%   
Low Rs818479 170.8%   
Sales per share (Unadj.) Rs298.6189.0 157.9%  
Earnings per share (Unadj.) Rs57.217.6 325.3%  
Cash flow per share (Unadj.) Rs58.434.0 171.7%  
Dividends per share (Unadj.) Rs17.003.00 566.7%  
Dividend yield (eoy) %1.80.5 347.5%  
Book value per share (Unadj.) Rs249.5176.7 141.2%  
Shares outstanding (eoy) m22.72805.12 2.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.13.0 103.3%   
Avg P/E ratio x16.332.5 50.1%  
P/CF ratio (eoy) x15.916.8 95.0%  
Price / Book Value ratio x3.73.2 115.5%  
Dividend payout %29.717.1 174.2%   
Avg Mkt Cap Rs m21,157459,724 4.6%   
No. of employees `0000.523.6 2.1%   
Total wages/salary Rs m40026,901 1.5%   
Avg. sales/employee Rs Th13,787.46,446.1 213.9%   
Avg. wages/employee Rs Th813.01,139.4 71.4%   
Avg. net profit/employee Rs Th2,643.3600.0 440.6%   
INCOME DATA
Net Sales Rs m6,783152,193 4.5%  
Other income Rs m3533,577 9.9%   
Total revenues Rs m7,136155,769 4.6%   
Gross profit Rs m1,61728,264 5.7%  
Depreciation Rs m2713,228 0.2%   
Interest Rs m61,142 0.5%   
Profit before tax Rs m1,93817,470 11.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m-5-775 0.7%   
Tax Rs m6322,501 25.3%   
Profit after tax Rs m1,30114,166 9.2%  
Gross profit margin %23.818.6 128.4%  
Effective tax rate %32.614.3 227.9%   
Net profit margin %19.29.3 206.0%  
BALANCE SHEET DATA
Current assets Rs m6,984108,141 6.5%   
Current liabilities Rs m2,05638,322 5.4%   
Net working cap to sales %72.645.9 158.4%  
Current ratio x3.42.8 120.4%  
Inventory Days Days9997 102.3%  
Debtors Days Days2474 32.2%  
Net fixed assets Rs m244109,411 0.2%   
Share capital Rs m2271,610 14.1%   
"Free" reserves Rs m5,441140,682 3.9%   
Net worth Rs m5,668142,292 4.0%   
Long term debt Rs m2536,621 0.1%   
Total assets Rs m7,901228,606 3.5%  
Interest coverage x353.316.3 2,168.5%   
Debt to equity ratio x00.3 1.7%  
Sales to assets ratio x0.90.7 129.0%   
Return on assets %16.56.7 246.8%  
Return on equity %22.910.0 230.5%  
Return on capital %34.010.0 342.0%  
Exports to sales %0.232.8 0.7%   
Imports to sales %36.30-   
Exports (fob) Rs m1549,883 0.0%   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1551,691 0.0%   
Fx outflow Rs m2,67721,033 12.7%   
Net fx Rs m-2,66230,658 -8.7%   
CASH FLOW
From Operations Rs m92314,628 6.3%  
From Investments Rs m317-8,540 -3.7%  
From Financial Activity Rs m-481-3,855 12.5%  
Net Cashflow Rs m7592,431 31.2%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.1 20.8 245.7%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 7.2 23.7 30.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 30.4 26.2 116.0%  
Shareholders   21,978 161,166 13.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   VENUS REMEDIES  SHASUN PHARMA  NOVARTIS  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS